HR Execs on the Move

Shearwater Health

www.shearwaterhealth.com

 
Shearwater Health, a global leader in Clinical Process Outsourcing (CPO®) has trained and augmented care teams with remote and onsite clinicians since 1973, reducing the strain on the healthcare system. With a global workforce of more than 4,000 expertly trained, clinical resources supported by innovative technology and Six Sigma process excellence, Shearwater Health offers both remote and onsite clinical expertise that can be deployed rapidly and securely. The organization recruits and trains nurses in skills such as utilization management, care management, patient care, and revenue cycle and supports their careers through education, including the US Nursing Licensure Exam.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Giri Namala
Chief Growth Officer Profile
Jennifer Bales
Chief Human Resources Officer Profile

Similar Companies

OPCO Laboratory Inc

OPCO Laboratory Inc is a Fitchburg, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CareBridge

CareBridge offers a patented EVV solution for personal care services, home health services, and health plan care managers. Originally launched in 2009, CareBridge has spent more than a decade refining our technology through multiple statewide rollouts.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

InfuSystem Holdings

Based in Madison Heights, MI, we are the leading provider of ambulatory infusion pumps and associated clinical services to oncologists and their patients in the U.S. We provide state-of-the-art continuous electronic ambulatory infusion pumps, along with appropriate supplies - and expert clinical support from oncology certified OCN® Registered Nurses.  In addition, we provide insurance expertise and advocacy service to our patients. More than 60% of oncology practices across all 50 states turn to InfuSystem as their full service source for cost-effective infusion pump management. We have 200+ employees earning the respect of patients and caregivers, physicians, nurses and pharmacists, case managers, billing specialists and claims administrators, by combining compassionate, evidenced-based care with knowledge, expertise and accuracy. InfuSystem is ambulatory infusion made easy.  

Roo-Lan Healthcare Center

Roo-Lan Healthcare Center is a Lacey, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.